Associations - KIF5B-RET fusion

BIOMARKER:

KIF5B-RET fusion

Entrez ID:

5979; 3799

Related biomarkers:

‹

›

KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
KIF5B-RET fusion KIF5B-RET fusion	Lung Cancer Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	everolimus + vandetanib Sensitive: C4 – Case Studies everolimus + vandetanib Sensitive : C4
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	cabozantinib tablet Resistant: C4 – Case Studies cabozantinib tablet Resistant : C4
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: D – Preclinical pralsetinib Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES